Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE) – Equities research analysts at Wedbush lowered their Q2 2018 EPS estimates for shares of Ultragenyx Pharmaceutical in a research report issued to clients and investors on Tuesday. Wedbush analyst D. Nierengarten now expects that the biopharmaceutical company will post earnings of ($2.11) per share for the quarter, down from their prior estimate of ($2.10). Wedbush has a “Outperform” rating and a $62.00 price target on the stock. Wedbush also issued estimates for Ultragenyx Pharmaceutical’s Q3 2018 earnings at ($0.78) EPS, Q4 2018 earnings at ($2.12) EPS and FY2018 earnings at ($4.47) EPS.

Ultragenyx Pharmaceutical (NASDAQ:RARE) last posted its quarterly earnings data on Thursday, November 2nd. The biopharmaceutical company reported ($1.87) earnings per share for the quarter, meeting analysts’ consensus estimates of ($1.87). The firm had revenue of $0.20 million during the quarter, compared to analysts’ expectations of $0.02 million. During the same quarter last year, the business earned ($1.64) earnings per share. The business’s quarterly revenue was up 81.8% on a year-over-year basis.

A number of other equities analysts have also weighed in on the stock. Zacks Investment Research lowered shares of Ultragenyx Pharmaceutical from a “hold” rating to a “sell” rating in a research report on Wednesday, October 25th. Barclays initiated coverage on shares of Ultragenyx Pharmaceutical in a research report on Wednesday, September 6th. They issued an “equal weight” rating and a $60.00 price objective on the stock. J P Morgan Chase & Co reiterated a “buy” rating and issued a $76.00 price objective on shares of Ultragenyx Pharmaceutical in a research report on Sunday, November 5th. Robert W. Baird lowered their price objective on shares of Ultragenyx Pharmaceutical from $85.00 to $80.00 and set an “outperform” rating on the stock in a research report on Friday, November 3rd. Finally, Canaccord Genuity reiterated a “buy” rating on shares of Ultragenyx Pharmaceutical in a research report on Tuesday, September 12th. Ten analysts have rated the stock with a hold rating and ten have given a buy rating to the stock. The company has a consensus rating of “Buy” and an average target price of $72.40.

Ultragenyx Pharmaceutical (NASDAQ RARE) opened at $45.57 on Friday. Ultragenyx Pharmaceutical has a 1 year low of $44.02 and a 1 year high of $91.35.

Several hedge funds and other institutional investors have recently modified their holdings of RARE. Sei Investments Co. purchased a new stake in shares of Ultragenyx Pharmaceutical during the 2nd quarter worth $125,000. SG Americas Securities LLC purchased a new stake in shares of Ultragenyx Pharmaceutical during the 3rd quarter worth $156,000. Tocqueville Asset Management L.P. boosted its position in shares of Ultragenyx Pharmaceutical by 8.0% during the 2nd quarter. Tocqueville Asset Management L.P. now owns 3,375 shares of the biopharmaceutical company’s stock worth $210,000 after purchasing an additional 250 shares in the last quarter. Pacer Advisors Inc. boosted its position in shares of Ultragenyx Pharmaceutical by 12.0% during the 2nd quarter. Pacer Advisors Inc. now owns 3,402 shares of the biopharmaceutical company’s stock worth $211,000 after purchasing an additional 365 shares in the last quarter. Finally, Kazazian Asset Management LLC acquired a new position in shares of Ultragenyx Pharmaceutical during the 2nd quarter worth $213,000. Institutional investors own 94.13% of the company’s stock.

COPYRIGHT VIOLATION NOTICE: This story was originally posted by The Cerbat Gem and is owned by of The Cerbat Gem. If you are accessing this story on another site, it was stolen and republished in violation of U.S. & international copyright legislation. The legal version of this story can be read at https://www.thecerbatgem.com/2017/12/10/q2-2018-earnings-forecast-for-ultragenyx-pharmaceutical-inc-issued-by-wedbush-rare.html.

About Ultragenyx Pharmaceutical

Ultragenyx Pharmaceutical Inc is a clinical-stage biopharmaceutical company. The Company is focused on the identification, acquisition, development, and commercialization of products for the treatment of genetic diseases. Its clinical-stage pipeline consists of two product categories: biologics (including a monoclonal antibody and an enzyme replacement therapy), and small-molecule substrate replacement therapies.

Earnings History and Estimates for Ultragenyx Pharmaceutical (NASDAQ:RARE)

Receive News & Stock Ratings for Ultragenyx Pharmaceutical Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Ultragenyx Pharmaceutical Inc. and related stocks with our FREE daily email newsletter.